AU2015330855A1 - Placenta-derived adherent cell exosomes and uses thereof - Google Patents
Placenta-derived adherent cell exosomes and uses thereof Download PDFInfo
- Publication number
- AU2015330855A1 AU2015330855A1 AU2015330855A AU2015330855A AU2015330855A1 AU 2015330855 A1 AU2015330855 A1 AU 2015330855A1 AU 2015330855 A AU2015330855 A AU 2015330855A AU 2015330855 A AU2015330855 A AU 2015330855A AU 2015330855 A1 AU2015330855 A1 AU 2015330855A1
- Authority
- AU
- Australia
- Prior art keywords
- placenta
- derived adherent
- exosomes
- adherent cell
- mir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 848
- 230000001464 adherent effect Effects 0.000 title claims abstract description 684
- 210000002826 placenta Anatomy 0.000 title claims abstract description 681
- 210000004027 cell Anatomy 0.000 claims abstract description 216
- 238000000034 method Methods 0.000 claims abstract description 108
- 239000000203 mixture Substances 0.000 claims abstract description 72
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 197
- -1 miR-451 Proteins 0.000 claims description 154
- 101000994378 Homo sapiens Integrin alpha-3 Proteins 0.000 claims description 81
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 81
- 102100032819 Integrin alpha-3 Human genes 0.000 claims description 81
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 81
- 102100027217 CD82 antigen Human genes 0.000 claims description 78
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 claims description 78
- 239000003795 chemical substances by application Substances 0.000 claims description 73
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 65
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 65
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims description 61
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims description 61
- 102100037241 Endoglin Human genes 0.000 claims description 60
- 102100025222 CD63 antigen Human genes 0.000 claims description 57
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims description 57
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims description 57
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 claims description 57
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 claims description 57
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 claims description 57
- 102100030859 Tissue factor Human genes 0.000 claims description 57
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 claims description 56
- 102100027221 CD81 antigen Human genes 0.000 claims description 56
- 102100037904 CD9 antigen Human genes 0.000 claims description 56
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 claims description 56
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims description 56
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 claims description 56
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 56
- 101000605020 Homo sapiens Large neutral amino acids transporter small subunit 1 Proteins 0.000 claims description 56
- 102100025305 Integrin alpha-2 Human genes 0.000 claims description 56
- 102100025304 Integrin beta-1 Human genes 0.000 claims description 56
- 102100032912 CD44 antigen Human genes 0.000 claims description 55
- 102100022002 CD59 glycoprotein Human genes 0.000 claims description 55
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 55
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims description 55
- 101001129927 Homo sapiens Leptin receptor Proteins 0.000 claims description 54
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 claims description 54
- 102100031775 Leptin receptor Human genes 0.000 claims description 54
- 102100026966 Thrombomodulin Human genes 0.000 claims description 54
- 101001133085 Homo sapiens Sialomucin core protein 24 Proteins 0.000 claims description 53
- 102100034258 Sialomucin core protein 24 Human genes 0.000 claims description 53
- 102100035893 CD151 antigen Human genes 0.000 claims description 51
- 101000946874 Homo sapiens CD151 antigen Proteins 0.000 claims description 51
- 102100022749 Aminopeptidase N Human genes 0.000 claims description 47
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims description 47
- 239000003550 marker Substances 0.000 claims description 40
- 108091079016 miR-133b Proteins 0.000 claims description 38
- 108091043162 miR-133b stem-loop Proteins 0.000 claims description 38
- 108091044721 miR-422a stem-loop Proteins 0.000 claims description 38
- 102000003729 Neprilysin Human genes 0.000 claims description 36
- 108090000028 Neprilysin Proteins 0.000 claims description 36
- 108091079658 miR-142-1 stem-loop Proteins 0.000 claims description 36
- 108091071830 miR-142-2 stem-loop Proteins 0.000 claims description 36
- 108091027943 miR-16 stem-loop Proteins 0.000 claims description 36
- 108091074057 miR-16-1 stem-loop Proteins 0.000 claims description 36
- 108091056204 miR-16-2 stem-loop Proteins 0.000 claims description 36
- 108091086421 miR-223 stem-loop Proteins 0.000 claims description 36
- 108091036689 miR-296 stem-loop Proteins 0.000 claims description 36
- 108091059456 miR-92-1 stem-loop Proteins 0.000 claims description 36
- 108091084336 miR-92-2 stem-loop Proteins 0.000 claims description 36
- 239000012634 fragment Substances 0.000 claims description 35
- 108091033753 let-7d stem-loop Proteins 0.000 claims description 35
- 108091079176 let-7d-1 stem-loop Proteins 0.000 claims description 35
- 108091036331 let-7d-2 stem-loop Proteins 0.000 claims description 35
- 108091086737 miR-630 stem-loop Proteins 0.000 claims description 35
- 108091091807 let-7a stem-loop Proteins 0.000 claims description 34
- 108091057746 let-7a-4 stem-loop Proteins 0.000 claims description 34
- 108091028376 let-7a-5 stem-loop Proteins 0.000 claims description 34
- 108091024393 let-7a-6 stem-loop Proteins 0.000 claims description 34
- 108091091174 let-7a-7 stem-loop Proteins 0.000 claims description 34
- 108700011259 MicroRNAs Proteins 0.000 claims description 33
- 108091050724 let-7b stem-loop Proteins 0.000 claims description 33
- 239000000427 antigen Substances 0.000 claims description 31
- 102000036639 antigens Human genes 0.000 claims description 31
- 108091007433 antigens Proteins 0.000 claims description 31
- 108091065218 miR-218-1 stem-loop Proteins 0.000 claims description 23
- 108091054980 miR-218-2 stem-loop Proteins 0.000 claims description 23
- 108091047658 miR-564 stem-loop Proteins 0.000 claims description 23
- 108091056924 miR-124 stem-loop Proteins 0.000 claims description 22
- 108091092839 miR-124-1 stem-loop Proteins 0.000 claims description 22
- 108091045380 miR-124-2 stem-loop Proteins 0.000 claims description 22
- 108091048120 miR-124-3 stem-loop Proteins 0.000 claims description 22
- 108091034147 miR-124-5 stem-loop Proteins 0.000 claims description 22
- 102100031780 Endonuclease Human genes 0.000 claims description 19
- 108010042407 Endonucleases Proteins 0.000 claims description 19
- 108020005004 Guide RNA Proteins 0.000 claims description 19
- 238000011534 incubation Methods 0.000 claims description 13
- 230000033115 angiogenesis Effects 0.000 claims description 11
- 230000008823 permeabilization Effects 0.000 claims description 8
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 8
- 229930182490 saponin Natural products 0.000 claims description 8
- 150000007949 saponins Chemical class 0.000 claims description 8
- 108091027963 non-coding RNA Proteins 0.000 claims description 6
- 102000042567 non-coding RNA Human genes 0.000 claims description 6
- 238000001125 extrusion Methods 0.000 claims description 5
- 238000011068 loading method Methods 0.000 claims description 5
- 238000000527 sonication Methods 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 210000000987 immune system Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 abstract description 11
- 230000003169 placental effect Effects 0.000 abstract description 4
- 210000004252 chorionic villi Anatomy 0.000 description 140
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 description 56
- 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 description 56
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 description 56
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 56
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 56
- 239000008177 pharmaceutical agent Substances 0.000 description 56
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 54
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 45
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 45
- 108091070501 miRNA Proteins 0.000 description 44
- 239000002679 microRNA Substances 0.000 description 44
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 43
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 43
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 43
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 43
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 41
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 41
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 41
- 108010075704 HLA-A Antigens Proteins 0.000 description 41
- 108010058607 HLA-B Antigens Proteins 0.000 description 41
- 108010052199 HLA-C Antigens Proteins 0.000 description 41
- 102000006354 HLA-DR Antigens Human genes 0.000 description 41
- 108010058597 HLA-DR Antigens Proteins 0.000 description 41
- 210000000229 preadipocyte Anatomy 0.000 description 39
- 238000000684 flow cytometry Methods 0.000 description 37
- 239000008194 pharmaceutical composition Substances 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 27
- 239000001963 growth medium Substances 0.000 description 25
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 23
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 23
- 108020004707 nucleic acids Proteins 0.000 description 23
- 102000039446 nucleic acids Human genes 0.000 description 23
- 150000007523 nucleic acids Chemical class 0.000 description 23
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 22
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 22
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 22
- 101000777599 Homo sapiens C-C chemokine receptor type 2 Proteins 0.000 description 22
- 239000000523 sample Substances 0.000 description 18
- 238000010459 TALEN Methods 0.000 description 16
- 238000002955 isolation Methods 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 12
- 230000001413 cellular effect Effects 0.000 description 10
- 102000008076 Angiogenic Proteins Human genes 0.000 description 9
- 108010074415 Angiogenic Proteins Proteins 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 108020004459 Small interfering RNA Proteins 0.000 description 9
- 230000001605 fetal effect Effects 0.000 description 9
- 239000004055 small Interfering RNA Substances 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 108091033409 CRISPR Proteins 0.000 description 8
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 8
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000004115 adherent culture Methods 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 5
- 108010024164 HLA-G Antigens Proteins 0.000 description 5
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 5
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 5
- 102000004890 Interleukin-8 Human genes 0.000 description 5
- 108090001007 Interleukin-8 Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102100029229 Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 Human genes 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102100032412 Basigin Human genes 0.000 description 4
- 102100027386 Beta-1,4-galactosyltransferase 6 Human genes 0.000 description 4
- 102100030621 Carboxypeptidase A4 Human genes 0.000 description 4
- 101000798441 Homo sapiens Basigin Proteins 0.000 description 4
- 101000937502 Homo sapiens Beta-1,4-galactosyltransferase 6 Proteins 0.000 description 4
- 101000772572 Homo sapiens Carboxypeptidase A4 Proteins 0.000 description 4
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 4
- 101000970023 Homo sapiens NUAK family SNF1-like kinase 1 Proteins 0.000 description 4
- 101000800546 Homo sapiens Transcription factor 21 Proteins 0.000 description 4
- 101000836755 Homo sapiens Type 2 lactosamine alpha-2,3-sialyltransferase Proteins 0.000 description 4
- 102100039373 Membrane cofactor protein Human genes 0.000 description 4
- 102100021732 NUAK family SNF1-like kinase 1 Human genes 0.000 description 4
- 108091006628 SLC12A8 Proteins 0.000 description 4
- 108010069296 ST6GalNAc V brain-specific GD1alpha synthase Proteins 0.000 description 4
- 102100036751 Solute carrier family 12 member 8 Human genes 0.000 description 4
- 102100033121 Transcription factor 21 Human genes 0.000 description 4
- 102100027107 Type 2 lactosamine alpha-2,3-sialyltransferase Human genes 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 102100035140 Vitronectin Human genes 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 230000000451 tissue damage Effects 0.000 description 4
- 231100000827 tissue damage Toxicity 0.000 description 4
- 238000005199 ultracentrifugation Methods 0.000 description 4
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 3
- 102100034608 Angiopoietin-2 Human genes 0.000 description 3
- 108010048036 Angiopoietin-2 Proteins 0.000 description 3
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 description 3
- 102100027207 CD27 antigen Human genes 0.000 description 3
- 102000024905 CD99 Human genes 0.000 description 3
- 108060001253 CD99 Proteins 0.000 description 3
- 102100035350 CUB domain-containing protein 1 Human genes 0.000 description 3
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 3
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 3
- 102100030886 Complement receptor type 1 Human genes 0.000 description 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 3
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 3
- 108010036395 Endoglin Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 3
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 3
- 108010014612 Follistatin Proteins 0.000 description 3
- 102000016970 Follistatin Human genes 0.000 description 3
- 102100035716 Glycophorin-A Human genes 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 3
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 3
- 108010010378 HLA-DP Antigens Proteins 0.000 description 3
- 102000015789 HLA-DP Antigens Human genes 0.000 description 3
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 3
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 3
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 3
- 101000867983 Homo sapiens C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 3
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 3
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 3
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 3
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 3
- 101001074244 Homo sapiens Glycophorin-A Proteins 0.000 description 3
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 3
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 3
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 3
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 3
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 3
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 3
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 3
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 3
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 3
- 101000934376 Homo sapiens T-cell differentiation antigen CD6 Proteins 0.000 description 3
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 3
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 3
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 3
- 101000803709 Homo sapiens Vitronectin Proteins 0.000 description 3
- 102100036721 Insulin receptor Human genes 0.000 description 3
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 3
- 102100032999 Integrin beta-3 Human genes 0.000 description 3
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 description 3
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 3
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 3
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 3
- 102100035488 Nectin-2 Human genes 0.000 description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 3
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 3
- 206010034576 Peripheral ischaemia Diseases 0.000 description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 description 3
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 3
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 3
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 102100038081 Signal transducer CD24 Human genes 0.000 description 3
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 3
- 102100025131 T-cell differentiation antigen CD6 Human genes 0.000 description 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
- 108010034949 Thyroglobulin Proteins 0.000 description 3
- 102000009843 Thyroglobulin Human genes 0.000 description 3
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 3
- 102100028786 Tumor necrosis factor receptor superfamily member 12A Human genes 0.000 description 3
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 3
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 208000037765 diseases and disorders Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229960002175 thyroglobulin Drugs 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 102100022454 Actin, gamma-enteric smooth muscle Human genes 0.000 description 2
- 102100040023 Adhesion G-protein coupled receptor G6 Human genes 0.000 description 2
- 102100034283 Annexin A5 Human genes 0.000 description 2
- 101100165655 Arabidopsis thaliana BRO1 gene Proteins 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- 102100024210 CD166 antigen Human genes 0.000 description 2
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 description 2
- 102100032404 Cholinesterase Human genes 0.000 description 2
- 102100022145 Collagen alpha-1(IV) chain Human genes 0.000 description 2
- 102100033781 Collagen alpha-2(IV) chain Human genes 0.000 description 2
- 102100037709 Desmocollin-3 Human genes 0.000 description 2
- 102100034578 Desmoglein-2 Human genes 0.000 description 2
- 102100038191 Double-stranded RNA-specific editase 1 Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100024108 Dystrophin Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100032050 Elongation of very long chain fatty acids protein 2 Human genes 0.000 description 2
- 102100021598 Endoplasmic reticulum aminopeptidase 1 Human genes 0.000 description 2
- 101710168245 Endoplasmic reticulum aminopeptidase 1 Proteins 0.000 description 2
- 102100021597 Endoplasmic reticulum aminopeptidase 2 Human genes 0.000 description 2
- 102100023882 Endoribonuclease ZC3H12A Human genes 0.000 description 2
- 102100031375 Endothelial lipase Human genes 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102100032790 Flotillin-1 Human genes 0.000 description 2
- 102100032523 G-protein coupled receptor family C group 5 member B Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000678433 Homo sapiens Actin, gamma-enteric smooth muscle Proteins 0.000 description 2
- 101000959602 Homo sapiens Adhesion G-protein coupled receptor G6 Proteins 0.000 description 2
- 101000780122 Homo sapiens Annexin A5 Proteins 0.000 description 2
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 2
- 101000943274 Homo sapiens Cholinesterase Proteins 0.000 description 2
- 101000901150 Homo sapiens Collagen alpha-1(IV) chain Proteins 0.000 description 2
- 101000710876 Homo sapiens Collagen alpha-2(IV) chain Proteins 0.000 description 2
- 101000968042 Homo sapiens Desmocollin-2 Proteins 0.000 description 2
- 101000880960 Homo sapiens Desmocollin-3 Proteins 0.000 description 2
- 101000924314 Homo sapiens Desmoglein-2 Proteins 0.000 description 2
- 101000742223 Homo sapiens Double-stranded RNA-specific editase 1 Proteins 0.000 description 2
- 101001053946 Homo sapiens Dystrophin Proteins 0.000 description 2
- 101000921368 Homo sapiens Elongation of very long chain fatty acids protein 2 Proteins 0.000 description 2
- 101000976212 Homo sapiens Endoribonuclease ZC3H12A Proteins 0.000 description 2
- 101000941275 Homo sapiens Endothelial lipase Proteins 0.000 description 2
- 101000847538 Homo sapiens Flotillin-1 Proteins 0.000 description 2
- 101001014684 Homo sapiens G-protein coupled receptor family C group 5 member B Proteins 0.000 description 2
- 101000840577 Homo sapiens Insulin-like growth factor-binding protein 7 Proteins 0.000 description 2
- 101000998020 Homo sapiens Keratin, type I cytoskeletal 18 Proteins 0.000 description 2
- 101000975496 Homo sapiens Keratin, type II cytoskeletal 8 Proteins 0.000 description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 2
- 101000629400 Homo sapiens Mesoderm-specific transcript homolog protein Proteins 0.000 description 2
- 101000588303 Homo sapiens Nuclear factor erythroid 2-related factor 3 Proteins 0.000 description 2
- 101100082597 Homo sapiens PDCD6IP gene Proteins 0.000 description 2
- 101000988401 Homo sapiens PDZ and LIM domain protein 3 Proteins 0.000 description 2
- 101001094807 Homo sapiens Paraneoplastic antigen-like protein 8A Proteins 0.000 description 2
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 2
- 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 description 2
- 101000735377 Homo sapiens Protocadherin-7 Proteins 0.000 description 2
- 101000999079 Homo sapiens Radiation-inducible immediate-early gene IEX-1 Proteins 0.000 description 2
- 101000823237 Homo sapiens Reticulon-1 Proteins 0.000 description 2
- 101000739767 Homo sapiens Semaphorin-7A Proteins 0.000 description 2
- 101000836075 Homo sapiens Serpin B9 Proteins 0.000 description 2
- 101000819088 Homo sapiens Transcription factor GATA-6 Proteins 0.000 description 2
- 101000635958 Homo sapiens Transforming growth factor beta-2 proprotein Proteins 0.000 description 2
- 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 2
- 101000613251 Homo sapiens Tumor susceptibility gene 101 protein Proteins 0.000 description 2
- 102000026633 IL6 Human genes 0.000 description 2
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 2
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 description 2
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 2
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010072582 Matrilin Proteins Proteins 0.000 description 2
- 102100033669 Matrilin-2 Human genes 0.000 description 2
- 102100026821 Mesoderm-specific transcript homolog protein Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100031700 Nuclear factor erythroid 2-related factor 3 Human genes 0.000 description 2
- 102100029177 PDZ and LIM domain protein 3 Human genes 0.000 description 2
- 102100035458 Paraneoplastic antigen-like protein 8A Human genes 0.000 description 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 2
- 102100033344 Programmed cell death 6-interacting protein Human genes 0.000 description 2
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 description 2
- 102100034941 Protocadherin-7 Human genes 0.000 description 2
- 102100036900 Radiation-inducible immediate-early gene IEX-1 Human genes 0.000 description 2
- 102100022647 Reticulon-1 Human genes 0.000 description 2
- 101001053942 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Diphosphomevalonate decarboxylase Proteins 0.000 description 2
- 102100037545 Semaphorin-7A Human genes 0.000 description 2
- 102100025517 Serpin B9 Human genes 0.000 description 2
- 102100021382 Transcription factor GATA-6 Human genes 0.000 description 2
- 102100030737 Transforming growth factor beta-2 proprotein Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 2
- 102100040879 Tumor susceptibility gene 101 protein Human genes 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000009692 acute damage Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000009693 chronic damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 108010080821 leucine-rich amelogenin peptide Proteins 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 102100026031 Beta-glucuronidase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 238000011993 High Performance Size Exclusion Chromatography Methods 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 description 1
- 101000896557 Homo sapiens Eukaryotic translation initiation factor 3 subunit B Proteins 0.000 description 1
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
- 201000005503 Hypoplastic left heart syndrome Diseases 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108700031126 Tetraspanins Proteins 0.000 description 1
- 102000043977 Tetraspanins Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- DVKFVGVMPLXLKC-PUGXJXRHSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)[C@@]1(OP(O)(O)=O)[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DVKFVGVMPLXLKC-PUGXJXRHSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 108091043161 miR-591 stem-loop Proteins 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 210000002487 multivesicular body Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000001492 polymer co-precipitation Methods 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
- C12N2502/025—Coculture with; Conditioned medium produced by embryonic cells extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021204332A AU2021204332A1 (en) | 2014-10-09 | 2021-06-25 | Placenta-derived adherent cell exosomes and uses thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462062046P | 2014-10-09 | 2014-10-09 | |
| US62/062,046 | 2014-10-09 | ||
| PCT/US2015/054629 WO2016057755A1 (en) | 2014-10-09 | 2015-10-08 | Placenta-derived adherent cell exosomes and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021204332A Division AU2021204332A1 (en) | 2014-10-09 | 2021-06-25 | Placenta-derived adherent cell exosomes and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2015330855A1 true AU2015330855A1 (en) | 2017-04-27 |
Family
ID=55653751
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015330855A Abandoned AU2015330855A1 (en) | 2014-10-09 | 2015-10-08 | Placenta-derived adherent cell exosomes and uses thereof |
| AU2021204332A Abandoned AU2021204332A1 (en) | 2014-10-09 | 2021-06-25 | Placenta-derived adherent cell exosomes and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021204332A Abandoned AU2021204332A1 (en) | 2014-10-09 | 2021-06-25 | Placenta-derived adherent cell exosomes and uses thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20170252379A1 (https=) |
| EP (1) | EP3204022B1 (https=) |
| JP (3) | JP2017536096A (https=) |
| CN (2) | CN107106615A (https=) |
| AU (2) | AU2015330855A1 (https=) |
| CA (1) | CA2964114A1 (https=) |
| DK (1) | DK3204022T3 (https=) |
| WO (1) | WO2016057755A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10900034B2 (en) | 2014-12-03 | 2021-01-26 | Agilent Technologies, Inc. | Guide RNA with chemical modifications |
| EP3280803B1 (en) | 2015-04-06 | 2021-05-26 | The Board of Trustees of the Leland Stanford Junior University | Chemically modified guide rnas for crispr/cas-mediated gene regulation |
| US20180177727A1 (en) | 2015-06-10 | 2018-06-28 | Board Of Regents, The University Of Texas System | Use of exosomes for the treatment of disease |
| CA3023349A1 (en) * | 2016-05-16 | 2017-11-23 | Exostem Biotec Ltd. | Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| AU2018266111B2 (en) | 2017-05-08 | 2024-11-07 | Flagship Pioneering Innovations V, Inc. | Compositions for facilitating membrane fusion and uses thereof |
| US20200163993A1 (en) * | 2017-05-09 | 2020-05-28 | Saint Louis University | Treatment of cancer and infectious diseases with natural killer (nk) cell-derived exosomes |
| US20200188440A1 (en) * | 2017-05-16 | 2020-06-18 | Exostem Biotec Ltd. | Methods of inhibiting aging and treating aging-related disorders |
| IL270864B2 (en) * | 2017-05-24 | 2025-01-01 | Nanosomix Inc | Identification of biomarkers on vesicles for diagnosis and prognosis of diseases and disorders |
| KR102109950B1 (ko) * | 2017-06-02 | 2020-05-12 | (주)엑솔런스바이오테크놀로지 | 체외충격파를 이용한 세포외소포체 내로의 표적물질 전달방법 |
| EP3672573A4 (en) | 2017-08-25 | 2021-05-26 | Codiak BioSciences, Inc. | PREPARATION OF THERAPEUTIC EXOSOMES USING MEMBRANE PROTEINS |
| KR102335710B1 (ko) * | 2017-10-31 | 2021-12-07 | (주)아모레퍼시픽 | 유산균 유래의 세포밖 베지클을 포함하는 면역조절용 조성물 |
| GB201718681D0 (en) * | 2017-11-13 | 2017-12-27 | Evox Therapeutics Ltd | Protein engineered extracellular vesicles |
| CA3082880A1 (en) * | 2017-11-16 | 2019-05-23 | Celularity Inc. | Cultivation of placenta to isolate exosomes |
| WO2019118817A1 (en) * | 2017-12-14 | 2019-06-20 | Mayo Foundation For Medical Education And Research | Purified exosome products, method of making, and methods of using |
| AU2018394238A1 (en) | 2017-12-28 | 2020-06-18 | Lonza Sales Ag | Exosomes for immuno-oncology and anti-inflammatory therapy |
| CN112384200A (zh) * | 2018-01-30 | 2021-02-19 | 希斯托金公司 | 低氧条件下培养的细胞衍生的胞外囊泡及其用途 |
| KR102235141B1 (ko) * | 2018-06-19 | 2021-04-05 | 푸와이 하스피틀, 차이니즈 아카데미 오브 메디컬 사이언시즈 앤드 페킹 유니언 메디컬 칼리지 | 약물 전처리에 기초한 간엽 줄기세포 유래 엑소좀 제조방법 |
| AU2019312212B2 (en) * | 2018-07-24 | 2024-10-10 | Mayo Foundation For Medical Education And Research | Compositions and methods involving transforming extracellular vesicles |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN109554341B (zh) * | 2018-12-18 | 2021-11-19 | 深圳先进技术研究院 | 无创超声处理细胞在制备外泌体中的应用、外泌体及其制备方法和应用 |
| CN110093274B (zh) * | 2019-05-13 | 2020-08-11 | 山东大学 | 一种增加细胞产生的细胞外囊泡数量的挤压装置及其应用 |
| PH12021553167A1 (en) * | 2019-06-19 | 2022-08-15 | Celularity Inc | Exosomes for disease treatment |
| WO2021210852A1 (ko) * | 2020-04-14 | 2021-10-21 | (주)녹십자웰빙 | 태반 유래 물질을 포함하는 항바이러스 조성물 |
| KR20220030552A (ko) * | 2020-09-03 | 2022-03-11 | (주)녹십자웰빙 | 태반 유래 엑소좀을 포함하는 간세포 증식 또는 항염증 효능 조성물 |
| JP2024534945A (ja) | 2021-09-10 | 2024-09-26 | アジレント・テクノロジーズ・インク | 化学修飾を有するプライム編集のためのガイドｒｎａ |
| WO2024102969A1 (en) * | 2022-11-10 | 2024-05-16 | Board Of Regents, The University Of Texas System | Use of fecal derivatives and fecal derived extracellular vesicles to enhance immunity |
| CN117050936A (zh) * | 2023-07-11 | 2023-11-14 | 清华大学 | 新亚群的人脐带间充质干细胞、其外泌体、制剂和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2316918B1 (en) | 2001-02-14 | 2015-07-01 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
| PL2471907T3 (pl) | 2005-12-29 | 2019-07-31 | Celularity, Inc. | Populacje komórek macierzystych łożyska |
| CA2734237C (en) | 2008-08-20 | 2019-07-02 | Anthrogenesis Corporation | Treatment of stroke using isolated placental cells |
| RU2539786C2 (ru) * | 2008-09-02 | 2015-01-27 | Плуристем Лтд. | Выращенные в прикрепленной к субстрату культуре клетки из ткани плаценты и их использование при лечении |
| GB2463401B (en) * | 2008-11-12 | 2014-01-29 | Caris Life Sciences Luxembourg Holdings S A R L | Characterizing prostate disorders by analysis of microvesicles |
| FR2950360B1 (fr) * | 2009-09-22 | 2011-11-25 | Centre Nat Rech Scient | Procede d'imagerie cellulaire pour la visualisation de la biogenese des microarns dans les cellules |
| DK2556145T3 (en) * | 2010-04-07 | 2016-11-07 | Anthrogenesis Corp | Angiogenesis using placental stem cells |
| EP2691101A2 (en) * | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| EP2721179A4 (en) * | 2011-06-16 | 2014-10-01 | Caris Life Sciences Luxembourg Holdings S A R L | BIOMARKER COMPOSITIONS AND METHOD THEREFOR |
| US11391741B2 (en) * | 2011-12-22 | 2022-07-19 | Theoria Science Inc. | Method of exosome analysis, reagent for exosome analysis, and analyzer for exosome |
| US9427450B2 (en) * | 2012-01-31 | 2016-08-30 | Xon Cells, Inc. | Therapeutic immune modulation by stem cell secreted exosomes |
| WO2014022852A1 (en) * | 2012-08-03 | 2014-02-06 | Aptamir Therapeutics, Inc. | Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders |
| AU2013302799B2 (en) * | 2012-08-13 | 2018-03-01 | Cedars-Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
| DK2931897T3 (en) * | 2012-12-12 | 2018-02-05 | Broad Inst Inc | CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS |
| EP2935628B1 (en) * | 2012-12-19 | 2018-03-21 | Caris Life Sciences Switzerland Holdings GmbH | Compositions and methods for aptamer screening |
| EP3608022A1 (en) * | 2013-03-15 | 2020-02-12 | The Trustees of Princeton University | Methods and devices for high throughput purification |
-
2015
- 2015-10-08 CN CN201580054280.7A patent/CN107106615A/zh active Pending
- 2015-10-08 CA CA2964114A patent/CA2964114A1/en active Pending
- 2015-10-08 US US15/517,438 patent/US20170252379A1/en not_active Abandoned
- 2015-10-08 AU AU2015330855A patent/AU2015330855A1/en not_active Abandoned
- 2015-10-08 DK DK15849339.5T patent/DK3204022T3/da active
- 2015-10-08 EP EP15849339.5A patent/EP3204022B1/en not_active Revoked
- 2015-10-08 CN CN202310711769.3A patent/CN116731958A/zh active Pending
- 2015-10-08 WO PCT/US2015/054629 patent/WO2016057755A1/en not_active Ceased
- 2015-10-08 JP JP2017518955A patent/JP2017536096A/ja active Pending
-
2020
- 2020-01-10 US US16/740,054 patent/US11173182B1/en not_active Expired - Fee Related
- 2020-11-06 JP JP2020185503A patent/JP2021040635A/ja not_active Withdrawn
-
2021
- 2021-06-25 AU AU2021204332A patent/AU2021204332A1/en not_active Abandoned
- 2021-10-07 US US17/495,985 patent/US20220241347A1/en not_active Abandoned
-
2022
- 2022-10-05 JP JP2022160666A patent/JP2023011580A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021204332A1 (en) | 2021-07-22 |
| JP2023011580A (ja) | 2023-01-24 |
| JP2017536096A (ja) | 2017-12-07 |
| DK3204022T3 (da) | 2021-03-08 |
| CN107106615A (zh) | 2017-08-29 |
| EP3204022A1 (en) | 2017-08-16 |
| WO2016057755A1 (en) | 2016-04-14 |
| US20170252379A1 (en) | 2017-09-07 |
| US11173182B1 (en) | 2021-11-16 |
| EP3204022B1 (en) | 2020-12-02 |
| CA2964114A1 (en) | 2016-04-14 |
| EP3204022A4 (en) | 2018-06-13 |
| CN116731958A (zh) | 2023-09-12 |
| US20220241347A1 (en) | 2022-08-04 |
| JP2021040635A (ja) | 2021-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11173182B1 (en) | Placenta-derived adherent cell exosomes and uses thereof | |
| AU2021203382B2 (en) | Therapeutic pooled blood apoptotic cell preparations and uses thereof | |
| US20220096560A1 (en) | Methods and compositions relating to mesenchymal stem cell exosomes | |
| JP6716564B2 (ja) | 安定したエクソソーム製剤の製造方法 | |
| US9877989B2 (en) | Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions | |
| JP2022538004A (ja) | 疾患治療用エキソソーム | |
| JP2021503301A (ja) | エキソソームを単離するための胎盤の培養 | |
| WO2023164241A1 (en) | Method for enriching muse cells and obtaining exosomes, microvesicles or the secretome therefrom | |
| WO2015076717A2 (en) | Mscs in the treatment of cardiac disorders | |
| US20220362341A1 (en) | Treatment of major depressive disorder by low dose interleukin-2 | |
| US20230141224A1 (en) | Fibroblast mediated expansion and augmentation of immune regulatory cells for treatment of acute respiratory distress syndrome (ards) | |
| HK1242969A1 (en) | Placenta-derived adherent cell exosomes and uses thereof | |
| HK1242969B (en) | Placenta-derived adherent cell exosomes and uses thereof | |
| HK1241290A1 (en) | Placenta-derived adherent cell exosomes and uses thereof | |
| EP4123019A1 (en) | Cord blood plasma-derived exosome or mimetic thereof and pharmaceutical use thereof | |
| JP2024507587A (ja) | 制御性Ｔ細胞（Ｔｒｅｇ）細胞外小胞組成物及び方法 | |
| US12011462B2 (en) | Stimulation of mesenchymal stem cell therapeutic activities by T regulatory cells | |
| US20230364143A1 (en) | Protection from ovarian failure by low dose interleukin-2 administration | |
| JP2022551916A (ja) | 新規調節性マクロファージ及びその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: CELULARITY, INC. Free format text: FORMER APPLICANT(S): ANTHROGENESIS CORPORATION |
|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |